MiNK Therapeutics soars over 500% after cancer therapy shows complete remission

Mink Therapeutics

11/07/2025 16:31

** Shares of drug developer MiNK Therapeutics INKT.O surge 522% to over three-year high of $48.10

** Stock set for best day on record, if gains hold

** Co says its experimental allogeneic cell therapy, agenT-797, showcased complete remission in a patient with advanced testicular cancer, as published in Oncogene

** Patient achieved durable clinical remission lasting over two years, with no evidence of disease and no adverse events such as cytokine release syndrome or graft-versus-host disease

** The patient, who had failed multiple treatments, including platinum-based chemotherapy, autologous stem cell transplant, and immune checkpoint inhibitors, received a single infusion of agenT-797 plus Bristol Myers Squibb's BMY.N cancer immunotherapy, nivolumab

** Including session moves, stock up 697% YTD

 (Reporting by Kamal Choudhury in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))